arrow_back Trending Legislation
Share share

Facilitating Access to Innovation in Cancer Care Act (FAIC Act)

This bill changes how Medicare pays hospitals for expensive cancer drugs to ensure patients can access the latest treatments. By paying for these drugs separately rather than as part of a bundle, it encourages hospitals to offer innovative therapies.
Key points
Requires separate Medicare payments for high-cost cancer treatments instead of bundling them into a single flat fee.
Improves patient access to innovative drugs and biologicals approved by the FDA since 2008.
Ensures hospitals are fairly reimbursed for providing advanced and expensive cancer care.
Sets a cost threshold ($350 per day in 2026) for treatments to qualify for separate payment.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Introduced
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
FAIC Act
Print number: HR 8032
Sponsor: Rep. Dunn, Neal P. [R-FL-2]
Process start date: 2026-03-20
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-flash-latest
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Facilitating Access to Innovation in Cancer Care Act (FAIC Act)

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is HR 8032.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2026-03-20.

What are the main provisions?

Key points include:

  • Requires separate Medicare payments for high-cost cancer treatments instead of bundling them into a single flat fee.
  • Improves patient access to innovative drugs and biologicals approved by the FDA since 2008.
  • Ensures hospitals are fairly reimbursed for providing advanced and expensive cancer care.
  • Sets a cost threshold ($350 per day in 2026) for treatments to qualify for separate payment.

What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Dunn, Neal P. [R-FL-2].

What is the latest detailed status?

The latest detailed status is: Introduced in House

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2026-04-13.

Analysis and Potential Impact of HR 8032

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health